# US 2025/0144114 A1 · Pharmaceutical compositions and methods for treating psychiatric disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144114 A1
- Document ID: US20250144114A1
- Status: Published application
- Kind: A1
- Application number: 19/018,731
- Filed: 2025-01-13
- Published: 2025-05-08
- Earliest claimed: 2022-07-08
- Assignees: LA PharmaTech Inc.
- Applicants: La Pharmatech Inc.
- Inventors: Jianmin Wang; Fengming Jia; Geping Cui
- Web page: https://patentgrep.com/patent/US20250144114A1

## CPC

- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of using a pharmaceutical composition comprising ebastine and alprazolam for treating patients suffering from one or more psychiatric disorders, such as major depressive disorder, generalized anxiety disorder, mild chronic depression, premenstrual dysphoric disorder are disclosed.

## Claims

### Claim 1

A method comprising:
administering a pharmaceutical composition to a patient having one or more psychiatric disorders selected from the group consisting of major depressive disorder, generalized anxiety disorder, mild chronic depression, premenstrual dysphoric disorder and symptoms thereof;
wherein the pharmaceutical composition comprises ebastine and alprazolam.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient has no sleeping disorder such as insomnia thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered to the patient in an oral solid or liquid form.

### Claim 4 (depends on 1)

The method of claim 1, wherein the ebastine is present in the pharmaceutical composition in an amount in the range of about 10 mg to about 30 mg.

### Claim 5 (depends on 1)

The method of claim 1, wherein the alprazolam is present in the pharmaceutical composition in an amount in the range of about 0.5 mg to about 5 mg.

### Claim 6 (depends on 5)

The method of claim 5, wherein the alprazolam is present in the pharmaceutical composition in an amount in the range of about 0.5 mg to about 3 mg.

### Claim 7 (depends on 1)

The method of claim 1, wherein the ebastine and the alprazolam are present in the pharmaceutical composition in synergistically effective amounts.

### Claim 8

A pharmaceutical composition for use in treating one or more psychiatric disorders selected from the group consisting of major depressive disorder, generalized anxiety disorder, mild chronic depression, premenstrual dysphoric disorder and one or more symptoms thereof, wherein the pharmaceutical composition comprises ebastine and alprazolam.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, wherein the pharmaceutical composition is formulated as an oral pharmaceutical dosage form.

### Claim 10 (depends on 8)

The pharmaceutical composition of claim 8, wherein the oral pharmaceutical dosage form is a solid form or a liquid form or a gel form.

### Claim 11

A pharmaceutical composition comprising ebastine and alprazolam for use in the treatment of a psychiatric disorder.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein the psychiatric disorder is selected from the group consisting of major depressive disorder, generalized anxiety disorder, mild chronic depression, and premenstrual dysphoric disorder.

### Claim 13 (depends on 11)

The pharmaceutical composition of claim 11, wherein the pharmaceutical composition is administered to the patient in an oral solid or liquid form.

### Claim 14 (depends on 11)

The pharmaceutical composition of claim 11, wherein the ebastine is present in the pharmaceutical composition in an amount in the range of about 10 mg to about 30 mg.

### Claim 15 (depends on 11)

The pharmaceutical composition of claim 11, wherein the alprazolam is present in the pharmaceutical composition in an amount in the range of about 0.5 mg to about 5 mg.

### Claim 16 (depends on 11)

The pharmaceutical composition of claim 11, wherein the alprazolam is present in the pharmaceutical composition in an amount in the range of about 0.5 mg to about 3 mg.

### Claim 17 (depends on 11)

The pharmaceutical composition of claim 11, wherein the ebastine and the alprazolam are present in the pharmaceutical composition in synergistically effective amounts.

### Claim 18 (depends on 11)

The pharmaceutical composition of claim 11, wherein the subject does not have a sleeping disorder.

### Claim 19 (depends on 18)

The pharmaceutical composition of claim 18, wherein the psychiatric disorder is selected from the group consisting of major depressive disorder, generalized anxiety disorder, mild chronic depression, and premenstrual dysphoric disorder.

### Claim 20 (depends on 18)

The pharmaceutical composition of claim 18, wherein the pharmaceutical composition is administered to the patient in an oral solid or liquid form.
